Literature DB >> 8549009

The key role of islet dysfunction in type II diabetes mellitus.

D Porte1, S E Kahn.   

Abstract

Fasting plasma glucose levels are constant from day to day in normal individuals. This constancy is due to a close co-ordination between glucose production by the liver and glucose uptake in peripheral tissues. This review focusses on the key role of the endocrine pancreas alpha- and beta-cells to provide this co-ordination. Non-insulin-dependent diabetes mellitus (NIDDM) is characterized by fasting hyperglycemia. The degree of fasting hyperglycemia, in turn, is correlated with the basal rate of hepatic glucose production. This increased rate of glucose release by the liver results in part from impaired hepatic sensitivity to insulin, but is largely due to reduced insulin secretion and increased glucagon secretion. Though basal immunoreactive insulin and glucagon levels in patients with NIDDM may appear normal when compared to those of healthy individuals, islet function testing at matched glucose levels reveals impairments of basal, steady-state, and stimulated insulin and glucagon secretion due to a reduction in beta-cell secretory capacity and a reduced ability of glucose to suppress glucagon release. The degree of impaired beta-cell responsiveness to glucose is closely related to the degree of fasting hyperglycemia, but in a curvilinear fashion. Thus, islet alpha- and beta-cell function is reduced by more than 50% in NIDDM by the time that clinical fasting hyperglycemia develops (140 mg/dL). The efficiency of glucose uptake by the peripheral tissues is also impaired due to a combination of decreased insulin secretion and defective cellular insulin action.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 8549009

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  9 in total

1.  Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice.

Authors:  N Irwin; P L McClean; F P M O'Harte; V A Gault; P Harriott; P R Flatt
Journal:  Diabetologia       Date:  2007-05-08       Impact factor: 10.122

2.  Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells.

Authors:  T Yada; M Nakata; T Shiraishi; M Kakei
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

3.  Phenothiazine neuroleptics signal to the human insulin promoter as revealed by a novel high-throughput screen.

Authors:  Alice Kiselyuk; Suzette Farber-Katz; Tom Cohen; Seung-Hee Lee; Ifat Geron; Behrad Azimi; Susanne Heynen-Genel; Oded Singer; Jeffrey Price; Mark Mercola; Pamela Itkin-Ansari; Fred Levine
Journal:  J Biomol Screen       Date:  2010-06-14

4.  Control of pulsatile 5-HT/insulin secretion from single mouse pancreatic islets by intracellular calcium dynamics.

Authors:  R M Barbosa; A M Silva; A R Tomé; J A Stamford; R M Santos; L M Rosário
Journal:  J Physiol       Date:  1998-07-01       Impact factor: 5.182

Review 5.  Human genetics illuminates the paths to metabolic disease.

Authors:  Stephen O'Rahilly
Journal:  Nature       Date:  2009-11-19       Impact factor: 49.962

6.  Individualized pharmacokinetic risk assessment for development of diabetes in high risk population.

Authors:  N Gupta; N H Al-Huniti; P Veng-Pedersen
Journal:  Diabetes Res Clin Pract       Date:  2007-03-19       Impact factor: 5.602

7.  A novel GPR40 agonist, CNX-011-67, suppresses glucagon secretion in pancreatic islets under chronic glucolipotoxic conditions in vitro.

Authors:  Mahesh Kumar Verma; Sanghamitra Biswas; Bhawna Chandravanshi; Korrapati Neelima; Anup M Oommen; Madanahalli R Jagannath; Baggavalli P Somesh
Journal:  BMC Res Notes       Date:  2014-09-03

Review 8.  Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations.

Authors:  David M Williams; Hannah Jones; Jeffrey W Stephens
Journal:  Diabetes Metab Syndr Obes       Date:  2022-02-04       Impact factor: 3.168

9.  Islet specific Wnt activation in human type II diabetes.

Authors:  Seung-Hee Lee; Carla Demeterco; Ifat Geron; Annelie Abrahamsson; Fred Levine; Pamela Itkin-Ansari
Journal:  Exp Diabetes Res       Date:  2009-01-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.